How much of the Q1 growth came from the extra fiscal week?

Medtronic estimates the 53rd week added about $570 million to Q1 organic revenue growth. That is roughly 6–7 percentage points of the 13.7% organic growth on the company's own estimate, so underlying growth excluding the extra week was materially lower. Investors should expect the comparison to normalize in later quarters of FY27.

Why did the company raise revenue guidance by only 50 basis points, and does that signal a strong rest of year?

The raise is modest at 50 basis points, to 7.25%–7.75%, even though Q1 beat the guidance midpoint by about 200 basis points. Part of the Q1 beat is timing and the extra week, which the company does not expect to repeat. The guidance raise therefore likely reflects a partial pass-through of the Q1 upside rather than a full re-rating of the year. The release does not give a detailed breakdown, so the implied Q2–Q4 growth rate is a matter for analyst modeling.

Why is the EPS guidance raise so small relative to the revenue raise?

Non-GAAP EPS guidance moved to $5.94–$6.00 from $5.90–$6.00, which raises only the low end. The release does not explain the margin or expense assumptions behind this. Possible drivers include continued innovation and commercial investment, the foreign exchange assumption (neutral to 1% accretive), and the Diabetes separation costs. These are inferences, not disclosed reasons.

What is the status of the Diabetes business separation?

Medtronic says the separation of its Diabetes business is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or a combination. A split-off is the company's current preferred structure, but no final decision has been made. Diabetes revenue grew 16.9% reported in Q1 to $843M. The release gives no timeline for completion.

How strong was cash generation and capital deployment this quarter?

Operating cash flow was $1.79B, up from $1.09B, and free cash flow was $1.29B, up from $584M. Capital deployment included $1.16B in acquisitions (Scientia Vascular and SPR Therapeutics), $921M in dividends, and $267M in share repurchases. Cash and equivalents fell to $1.69B at quarter end, with net debt activity (including $812M of change in current debt) contributing to the funding mix.

MDT 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed September 1, 2026. Cited figures are marked; the original filing is the authoritative source.

Medtronic plc (NYSE: MDT) reported first quarter fiscal 2027 results (quarter ended July 31, 2026) that beat its own guidance and led the company to raise full-year guidance.

Reported and organic revenue each grew 13.7% to $9.756 billion^a, roughly 200 basis points above the guidance midpoint. GAAP diluted EPS was $1.14, up 40.7%, while non-GAAP diluted EPS was $1.45, up 15.1%. Management attributes the outperformance to breadth across the portfolio, not just one franchise.

Cardiovascular grew 18.9%^b organically, led by 88% growth in Cardiac Ablation Solutions and 15% growth in Cardiac Rhythm Management. Neuroscience grew 9.3% and Medical Surgical grew 10.2%. Investors should weigh two points when reading the headline growth.

First, the quarter included a 53rd (extra) week in the first fiscal month, which the company estimates added about $570 million^c, or roughly 6.6 points, to Q1 organic growth. Second, the company's FY27 guidance was raised modestly: organic revenue growth rises 50 basis points to 7.25%–7.75%, and non-GAAP EPS guidance moves to $5.94–$6.00 from $5.90–$6.00, with a neutral to 1% accretive currency benefit. The EPS raise is small relative to the revenue raise, so the implied margin or cost outlook is less changed than the top line.

Other items of note include the Scientia Vascular and SPR Therapeutics acquisitions, which closed in the quarter, and the Pi-Cardia strategic investment. Free cash flow was $1.29 billion^d, up from $584 million a year earlier.

The company also reiterated that the Diabetes separation is still in progress, with a split-off as the current preferred structure but no final decision yet. This 8-K furnishes the earnings press release under Item 2.02 and does not itself contain new financial statements or forward-looking commitments beyond the release.

02—Key points

Key Highlights

Q1 FY27 revenue of $9.756B grew 13.7% reported and organic, about 200 bps above the guidance midpoint; the extra fiscal week contributed roughly $570M to organic growth.
FY27 organic revenue growth guidance raised 50 bps to 7.25%–7.75%; non-GAAP diluted EPS guidance raised to $5.94–$6.00 from $5.90–$6.00.
Cardiovascular grew 18.9% organically, led by Electrophysiology Therapies (+29.1% organic), with Cardiac Ablation Solutions up 88% and Cardiac Rhythm Management up 15%.
Neuroscience grew 9.3% organically and Medical Surgical grew 10.2%; Diabetes revenue rose 16.9% reported (14.9% organic) to $843M.
GAAP diluted EPS was $1.14 (up 40.7%) versus non-GAAP diluted EPS of $1.45 (up 15.1%); non-GAAP operating margin was 23.7%, up 10 bps.
Free cash flow was $1.29B versus $584M a year earlier, supported by higher operating cash flow of $1.79B.
Completed the Scientia Vascular and SPR Therapeutics acquisitions (about $1.16B in acquisition cash outflow), and announced a strategic investment in Pi-Cardia and a partnership with Cornerstone Robotics; the Diabetes separation remains in progress, with split-off as the preferred structure.

03—Questions

Frequently Asked Questions

How much of the Q1 growth came from the extra fiscal week?
Medtronic estimates the 53rd week added about $570 million to Q1 organic revenue growth. That is roughly 6–7 percentage points of the 13.7% organic growth on the company's own estimate, so underlying growth excluding the extra week was materially lower. Investors should expect the comparison to normalize in later quarters of FY27.
Why did the company raise revenue guidance by only 50 basis points, and does that signal a strong rest of year?
The raise is modest at 50 basis points, to 7.25%–7.75%, even though Q1 beat the guidance midpoint by about 200 basis points. Part of the Q1 beat is timing and the extra week, which the company does not expect to repeat. The guidance raise therefore likely reflects a partial pass-through of the Q1 upside rather than a full re-rating of the year. The release does not give a detailed breakdown, so the implied Q2–Q4 growth rate is a matter for analyst modeling.
Why is the EPS guidance raise so small relative to the revenue raise?
Non-GAAP EPS guidance moved to $5.94–$6.00 from $5.90–$6.00, which raises only the low end. The release does not explain the margin or expense assumptions behind this. Possible drivers include continued innovation and commercial investment, the foreign exchange assumption (neutral to 1% accretive), and the Diabetes separation costs. These are inferences, not disclosed reasons.
What is the status of the Diabetes business separation?
Medtronic says the separation of its Diabetes business is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or a combination. A split-off is the company's current preferred structure, but no final decision has been made. Diabetes revenue grew 16.9% reported in Q1 to $843M. The release gives no timeline for completion.
How strong was cash generation and capital deployment this quarter?
Operating cash flow was $1.79B, up from $1.09B, and free cash flow was $1.29B, up from $584M. Capital deployment included $1.16B in acquisitions (Scientia Vascular and SPR Therapeutics), $921M in dividends, and $267M in share repurchases. Cash and equivalents fell to $1.69B at quarter end, with net debt activity (including $812M of change in current debt) contributing to the funding mix.

04—Continue

← View all 8-K filings